A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Latest Information Update: 21 Oct 2022
At a glance
- Drugs SP 624 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Sirtsei Pharmaceuticals
- 17 Oct 2022 Interim results published in the Media Release
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 26 May 2022 According to an Arrivo BioVentures media release, the company expects top-line data in early Q4 2022.